Failure of Adjusted Doses of Subcutaneous Heparin to Prevent Thromboembolic Phenomeqa in Pregnant Patients
LJf&aives. Tbis report describes our experience witb the use of an antieoagukmt regimen of adjusted doses of subsutaneons beparbr doting pregnancy in women with cardiac valve prostbeses.
Bu&grotouf. Gravld patients witb prosthetic beart valves re. qube long-term antleoagnlant therapy. To avoid tbe increased brcldence of fetal morbidity and mortalii associated witb tbe use uf wmuarbt agents in such patients duping pregmmcy, anticoap tdatitm with mdJeutattwus beparln bas been suggested. contraversy exists concembrg tbe appropriate treatment of tbese patients.
&thodv. party pregnancies in 37 women witb prostbetle heart valves were prospectively followed up. Sobeutaueons beparin was admlnistemd from tbe 6tb mrtll tbe end of tbe 12th week and in tbe last 2 weeks of gestation. Heparln was given every 8 b in tbe &st36casesandevery6bintbelsst4cases,andtbedose adjusted to maintain tbe aetivated partial tbmmboplastin time at 15 to 2.3 times tbe control level. Acenocoumarol was used at other times* In patients with mechanical prosthetic heart valves, long-term anticcmgulaut therapy is mandatory to prevent thromboembolic phenomena. Anticoagulation is also necessaty in patients with a bioprosthesis who have atriaf fibrillation and a large left atrium. The risk of maternal thromboembohc events is heightened during pregnancy because of the patient's hypercoagulabie state, which is characterized by increased levels of certain ckrtting factors and of fibrinogen and platelet adhesiveness (1) .
Coumarin derivatives provide effective protection against thromboembolism, but their use in pregnancy is associated with an augmented rate of abortion and the risk of coumarinJfesul@. Tbe incidence rate of spontaneous abortions was 37.5% there was one neonatal de&b (2.5%) doe to cerebral hemorrhage. No signs of eomnarln-induced embryopatby were found in any of tbe 16 live-born infants studii by tbe geneti~st. One motber died of gastrointestinal bleeding wbii reeelving oral aaticoagubmt agents. There were two cases of fatal massive thrombosis of a mitral tilting-disk pmstbesis dmlng beparln tberapy. Tbe study was interrupted after tbe last of tbese two cases.
Corwk.&rts. Tbe regbnen of adjusted doses of snbcntaneous bepatin used ln tbis study is not elfective to prevent thrombosis of mecbanll valve prostheses during pregnancy. The ase of beparbr from tbe 6tb to tbe 12tb week of gestation does not decrease tbe b&b incidence of fetal wastage associated wltb anticoagubmt therapy. Coumarbt agents provide adequate pro&&ion against tbmmboembolism durlng pregnancy in patients witb mecbanlcal valve prostbeses.
(J Ant cbu cordial 1996;27:1698-703) induced embryopathy (2-4). It has previously been shown (5) that the teratogenic effect of coumarin derivatives may be prevented if these agents are discontinued from before the 6th until the 12th week of pregnancy. Several investigators have advocated substituting subcutaneous heparhr for oral coumarin derivatives, either throughout the gestation period (6) (7) (8) (9) or during the 1st trimester and the last weeks of pregnan9 (2, 5, (10) (11) (12) . However, neither the efficacy of heparln in preventing thromboembolism nor its safety with respect to fetal wastage has been fully evaluated. Moreover, the exact dosage and the proper method of monitoring remain unctear.
For pregnant women with mecbanicai prosthetic heart valves or bibprostheses and either atrial 6briUation or previous thromboembolii events, Ginsberg and Barr& (13) with mechanical heart valves, bringing an increased risk of both thromboembolism and bleeding to mother and fetus. It ap pears, therefore, that arguments continue :F to whether such patients are best managed with oral anticoagulant agents or with heparin. We therefore report our experience with the use of adjusted doses of subcutaneous heparin in the first trimester and the last 2 weeks of gestation in 40 pregnancies in 37 women with prosthetic heart valves.
St&y patients. We prospectivety followed up 40 pregnancies in 37 women with prosthetic heart valves. The age of the patients at the beginning of pregnan9 ranged from 18 to 40 years (mean 2 SD 27.7 + 6.2 Years). All women in the study were in New York Heart Association fmtctional dass I or lh 17 (42.5%) had sinus rhythm and 23 (57.5%) had chronic atrial fibriM.ion. Thirty-three patients (82.5%) received treatment with different combinations of digitalis and diuretic drugs.
lbsthetii valve-a. The diEerent types of valve p;ostheses used and their sites of implantation am shown in Table 1 . The valve model inserted depended on the preference of the surgeon and reflected common "&e at the time of operation. The 13 patients with bii were receiving long-term anthagulaut therapy because of atrial fibrillation and a large left atrium.
Metharlot &m.Whenthediagno&ofpreg-nancywasestablishedbyagynecologis&atorbeforetbe6th week of pregnancy, the mother was admitted to the National Institute of Card&gy. The admh&mtion of aceM)(xwIIIILfd wasliiscoutiuuedandtreatmeutwith §ubcutaueousheparbl, 7~OOUevery8hwasbegtm.Thedoseofhepatinwasadjusted until the activated partial thrombopbtin time, dekmnined 4 h ~rthelitst~,~be(weenlSt025timestheoontrof level (kaoli-crepbttlin reagent, Pathnomtio, Ekhhg). IBe pa~t~~~~~~~~~~fo~ up every 2 weeks at the anticoagulant clinic. An average dose of 8,055 2 1,308 U every 8 h was given to the first 36 mothers in the study. In the last 4 cases, the interval between injections was reduced and the mothers received an average of 5,125 -C 1,030 U of subcutaneous heparin every 6 h, again to maintain the activated partial thromboplastin time between 1.5 to 25 times the control level. Treatment with acenocoumarol was resumed in all cases after the end of the 12th week to maintain an international normalized ratio (INR) of 3.0 to 3.5. In this period the patients were seen at the anticoagulant clinic at least every 4 weeks. All mothers were referred for delivery to an obstetric hospital speciahzing in high risk pregnancies, where subcutaneous adjusted heparin was again administered, as dexrii, during the last 2 weeks of pregnancy. Heparin was discontinued at the onset of labor and reinitiated 24 h after delivery. Acenocoumaroi therapy was begun as soon as possible and heparin discontinued once the prothrombin rates were within the therapeutic range. In some patients who had early labor, acenocoumarol was not discontinued until immediately before delivery. The anticoagulant regimen used in these patients was that thought best at the time. Nevertheless, the fetal and maternal risks were thoroughly discussed with every patient and her husband, and written informed consent was obtained. Those patients who refused or could not comply with the heparin regimen, or whose pregnancy was detected after the 6th week, received acenocoumarol during all 3 trimesters and are not included in this study. Sixteen of the 22 liie-born babies were examined by a geneticist.
Results hgrmcy 013tamtes. There were 15 spontaneous abortions (37.5%; 95% conlidence interval [CT] 22.7% to 54.2%); all ocemed iu the first trimester of gestation. Pregnanq resulted in Iii births in 22 cases (55.O%). There were 16 vaginal deliveries (16 1727961 of U; 95% Cl 49.8% to 89.3%); a cesaman section was performed in 6 patients (6 [273%] of 22; 95% Cl 10.7% to 50.2%) because of obstetric indications or because labor developed while coumarin therapy was still in effect.
f&mrnai~astd~.There,wasaminor episodeofcerebralembotisminthelsttrimesterofpreknancy in a patient with a mitral Starr-Edwards pro&e& white heparin treatment was still in effect. Three women died (75%; %%Cl1.6%to2O.4%)duringthecourseofthestndy.Oneof tbethree(Case2intheseries)arrivedata~ereatbospitafin profotmd shock seamday to upper gastmmtestinai bleeding anddiedintbe14thweekofpmgnanq.Acemxwoaaroihad been&stitutedforbepariiattbeendofthel2thweekof geatationandthelNRhadbeenadequatelweekbefomher death.lnthesecondpatient(Case36intheseries),msssive thromhosisofaRj&k-ShileaorticpmstheGdeveloped,and shediedlhaftertheonsetof.ymptomsinthe8thweekof gestation.shehadbeenreceiving95OOuofsabartaneoas heparinevery8hsincetheendofweek4.Thistmforttmate result was of serious concern and we therefore changed the guidelines for heparin administration to delivery of the dose every 6 h instead of every 8 h, with adjustment of the dose, as before, until the activated partial thromboplastin time was 1.5 to 2.5 times the control level. The third patient (Case 40 in the series) had thrombosis of a Bjiirk-Shiley mitral prosthesis in the 12th week of pregnancy while receiving 6,500 U of subcutaneous heparin every 6 h. She died in the immediate postoperative period. Both patients with thrombosis had strictly followed their heparin treatment, and the careful monitoring of the activated partial thromboplastin time had shown values in the target therapeutic range (55 to 95 s; control 30 to 35 s). After this death, it was concluded that the regimen of subcutaneous heparin employed was not effective to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses. After consultation with the Institute's Bio-Ethics Committee, the study was ended earlier than planned.
No thromboembolic accidents were observed in any of the mothers while they were receiving acenocoumarol. There was no maternal morbidity in the patients with bovine pericardium hioprostheses.
A woman with a mitral Bjork-Shiley prosthesis experienced heart failure with pulmonary congestion during the 13th week of gestation. She was successfully treated with furosemide and had a full-term pregnancy and normal vaginal deliiety. All other patients remained in hemodynamically stable condition throughout pregnancy and delivery. One patient had severe vaginal bleeding during deliiety and puerperium requiring Mood transfusions. Two other mothers had minor peripartum hemorrhagic complications. One had an inguinal hematoma and the other had transient hematuria. No cases of osteoporosis or thromboqtopenia were detected.
Fetal outcomes. Eight (36.4%; 95% CI 17.2% to 59.3%) of the 22 neonates were born prematurely (before the 37th week of gestation). Three of these eight infants had low biih weight (<2,500 g). One additional infant had a myelomeningocele. There was one neonatal death due to cerebral hemorrhage. In this case, labor had begun in the 35th week of pregnancy while the mother was still under treatment with coumarin agents and it had progressed for some time before the patient arrived at the obstetrics hospital where a cesarean section was performed. Except for this infant and one other infant who was born at the 28th week of gestation with a bii weight of 1,000 gY the 22 lie-born neonates had normal Apgar scores. There were no signs suggestive of coumarin~mduced embryop athy in any of the 16 live-born infants studied by the geneticist. NO cases of central nervous system abnormalities or optic nerve atrophy were observed.
Discussion
Ontsomenf pfegnaacg. Cmmmin compounds and their derivatiwes cross the placental barrier, and their use by the mother results in an hmmased incidence. of fetal mortality and JACC Vol. 27, No. 7 June 1996:169&iU3 morbidity. Treatment with these agents during pregnancy is associated with a high spontaneous abortion rate ranging between 16.2% and 44% (2, 3, 5, (16) (17) (18) (19) (20) . It was thought that heparin could be an effective alternative method of anticoagulation because it has a high molecular weight and does not cross the placental barrier. Ginsberg et al. (9) reported a low incidence of spontaneous abortion (3 [8.8%] of 34) in patients who were given subcutaneous heparin therapy for the prevention or treatment of venous thromboembolism within the 1st 20 weeks of pregnancy. In a review of reported studies, Ginsberg and Hirsb (21) concluded that, when pregnancies associated with comorbid maternal conditions that could independently cause adverse fetal outcomes were excluded, the rate of these adverse outcomes in heparin-treated mothers was similar to that found in a normal population. Unfortunately, in the present study, the incidence rate of spontaneous abortion was 37.5%, which is comparable to that observed in mothers treated with coumarin derivatives during the first trimester. Li?ewise, using adjusted doses of heparin in the first trimester, Lee et al. (11) found nine spontaneous abortions in 18 cases (50%). The high fetal wastage rate observed in the present study may be related to an underlying high baseline risk of the patients. In fact, ail patients conceived while receiving coumarin and were treated with this agent for 4 to 6 weeks before the initiation of heparin therapy. It is also probable that these abortion rates could be explained by placental hemorrhage, which may occur during effective anticoagulation with either coumarin agents or heparin.
Fetal morbidity. Fetal exposure to coumarin agents during the first trimester may result in an embryopathy whose features are teiecanthus, hypoplasia of the nose, small nasal bones, depressed nasal bridge, hypoplastic alae nasi, choanal stenosis with upper airway obstruction and punctate dysplasia of the epiphyses of the long bones, as well as of the cervical and lumbar vertebral end plates. Previous studies from thii institution looked for congenital malformations after maternal coumarin therapy. The typical form of coumarin embryopathy among the infants exposed to coumarin derivatives between the 6th and 12th weeks of gestation was found in 1 of 38 infants studied in one of our series (2) and in 2 of 35 infants in a second study (5) , for a combined total of 4.1%. In these previous reports from our institution, some additional infants, 10 (13.7%) of 73, had minor abnormalities, such as a slight hypoplasia of the nasal bones and of the arae nasi, suggesting less severe examples of the syndrome. Recent studies by Sareli et al. (16) and by Born et al. (17) found an incidence rate of 5.9% (2 of 34) and 10.0% (3 of 30), respectively, in neonates born of mothers who were treated with coumarin derivatives throughout pregnancy. It has been shown (5) that the terato-, genie effects of the coumarin agents may be prevented if these agents are discontinued from before the 6th until the end of' the 12th weekof gestation (5) . Thus, in the present study, none of the 16 infants examined by the clinical geneticist had any of the features of coumarin-induced embryopathy.
It has been repormd (421) that central nervous system abnormalities may occur in the ot@riug in association with maternal coumarin therapy during any trimester. However, no cases of neurologic abnormalities were observed in this series or in our previous studies QJ). The presence of myelorheningocele in one infant cannot be attniuted to the use of oral anticoagulant agents. Finally, the neonatal death due to cerebral hemorrhage underlines the fact that the trauma of labor, when it develops while the mother is still receiving coumarin therapy, may be a major factor in the production of perinatai intracraneal bleeding. Other cases of neonatal death due to intracranial hemorrhage have been reported (2, 16, 17) in infants of mothers who were given warfarin until term. The relative immaturity of the fetal clotting system renders the fetus hypersensitive to the usual doses of coumarin agents (22) . Thus, the feius may continue to have effective anticoagulation for 7 to 10 days after cessation of warfarin therapy. There is an increased risk if labor begins prematurely while the mother is still taking coumarin agents, and emergency cesarean section may be needed to protect the fetus against the danger of cerebral hemorrhage associated with the trauma of vaginal delivery.
Maternal mortaIIty and murbhllty. Gravid women who have mechanical prostheses require prophylaxis against thromboemboiism. The omission of effective anticoagulant therapy dutig pregnancy considerably increases the danger of prosthetic thrombosis and of systemic embolization. In 68 pregnant patients with mechanical cardiac valve prostheses treated with dipyridamoie and aspirin in the early part of our experience (2), there were three instances of massive thromboses that occluded a mitral or aortic caged-bail valve prosthesis and a 25% incidence rate of cerebral embolism. Because of the high incidence of fetal wastage and the risk of teratogenic effects when the fetus is exposed to coumarin derivatives, the substitution of heparin for oral anticoagulant agents during pregnancy has been advised (2.5-12). In a previous study from our institution (S), the use of fixed low doses of subcutaneous heparin, 5,000 U every 12 h, administered from the 6th to the 12th week and the last 2 weeks of gestation, did not protect against prosthetic valve thrombosis. There were three cases of thrombosis of a tilting-disk mitral prosthesis in a group of women treated with these small doses of heparin. Likewise, Wang et al. (10) and Thomas et al. (23) found that this regimen was not efficacious to prevent thromboembolii phenomena in their patients.
The possibility that larger and adjusted doses of subcutaneous heparin with monitoring of the activated partial tbrombopiastin time might be effective has been suggested (ll-13,21). Lee and co-workem (11) adjusted the dose of subcutaneous heparin, administered every 8 h to prolong the activatedpartialthmmboplastiutimeatL5timestheax@ol value, during the 1st trimester and last 3 weeks of gestation in 18 pregnancies in 16 wvmen with cardiac valve postheses. There were no thromboemboIIc complications in the nine pregnancies that were continued to term. In the present study subcutaneousheparinwasadministeredfmmthe6thtothe 12thweekandhtheIast2weeksofgesthmIntkIirst36 casesthedosewasgivenevery8handitwaaa@rstedtO In an attempt'to avoid possible periods without anticoagulant effect, we shortened the interval between doses of subcutaneous heparin to every 6 h in the last four cases of the study, again to maintain an activated partial thromboplastin time at 1.5 tc 2.5 times the control level. Unfortunately, Patient 40 also had a massive thrombosis of a mitral standard BjarkShiley valve. In both these cases and in the episode of cerebral embolism observed in :be present study, there was strict adherence of the patients to the protocol and careful monitoring had shown anticoagulation in the target activated partial thrombopiastin time therapeutic range. From our data it is clear that the dosage of subcutaneous heparin employed does not provide adequate protection against thromboembolism in pregnant patients with mechanical prostheses and its use has been abandoned at our institution.
Cases of thromboses of mechanical cardiac valves related to heparin treatment have been reported (5,10,14,20,23-2g) . Sbarouni and Oakley (14) recently reported a retrospective multicenter survey from major European centers. The information was obtained by questionnaire. There were 13 cases of thrombosis of a prosthetic valve and eight major embolii events in 151 pregnancies observed in 133 women with mechanicat vaIves. Ten of the 13 women with thrombosed valves and 5 of the 8 patients with arterial embolism were taking heparin. Subcutaneous heparin was administered throughout the duration of pregnancy in several reported cases (92529). Among 34 pregnancies in patients with mechanical valves treated with this regimen, Sbarouni and Oakley (14) reported that 24% were complicated with valve thrombosis and 12% by embolic events. It has been suggested (13) that the different and perhaps inadequate heparin dosing and target therapeutic rangeemployedintheseshtdiesmayexplainthehighratesof thromboembolic phenomena. It is possiie that s&cutaneous heparin may be effective if given in a larger dose, ie, 35,ooO U daiIy. It has been suggested (1~) that subcutaneous heparin should be initiated in doses of 17,500 to 20,000 U every 12 h, with dose adjustment to a minimum target activated partial thromboplastin time ratio of at least lwice control level. However, these regimens have not been tested. Simila& no experience with the lrse of low molecular weight heparin has been reported.
Inthisseries,tbeme&anicaIpm&esesinwhichthromh+ sis developed were of the Bj&k-Shiley .stamM type. Never generationme&ani&heartvalve5areknowntohavea relatively low thrombcn&o&c pmtile (3031). Sareli et al. (16) foiiiid no thromboembolic compli@ious in 39 patients with Medtro&-Hall~or7womenwithSLJudeMedical modeIstreatedwithw;lrfarinthrougboutpregnancy.~ ofthesevatvzz3mayre&tinalowerincidenceofthromhoem-boiiceventsinpregDantpatieil~treatedwitbheparin,butthe a&lahIe&aarescarce.Inaretroapectivu:coope~study, -et~ (27) h&&al prostheses who were being treated with caleiheparin. In addition, Go&Lx-Santos et aI (28) described prosthetic thrombosii in a patient with a Medtronic-Hall valve who was &t receiving cakiheparin. Because birostheses are less thrombogenic than mechanical prostheses, it seems probable that adjusted doses of heparin may be adequate therapy in the 1st trimester and the last 2 weeks of pregnancy in patients with these vaIves who require anticoagulation because of atria1 fibriIIation, large left atrium or a history of previous systemic embolism. In this study, there was no maternal morbidity in the patients with bovine pericardium cardiac valves who received heparin.
Coumarin derivatives are effective to prevent thromboemboIic complications during pregnancy in patients with mechanical valves (14-16). There were no thromboembolic accidents in the present study during treatment with these agents. In one of our previous reports there was a 2.3% incidence of systemic emboIism in 128 gravid women treated with acenocoumarol throughout pregnancy (2) . In addition, in a second study (5) there were no thromboembolic accidents in 72 pregnancies while the mothers received coumarin agents in the 2nd and 3rd trimesters. Born et ai. (17) reported a 7.5% incidence rate (3 of 40) of mechanical vaIve thrombosis in patients being treated with coumarin derivatives. However, two of these thrombotic accidents occurred in patients with inadequate anticoagtda~ tiun.
Recommendatkms. In women with mechanical heart valves no method of anticoagulation during pregnancy is entirely free of risk, and all management policies must be based on an estimate of risk benefit ratio. There is a 4.1% risk of embryopathy when coumarin compounds or derivatives are used frnm the 6th to the 12th week of gestation. Howcvcr, the obvious alternative, subcutaneous heparin, with the doses adjusted to increase the activated partial thromboplastin time from 1.5 to 25 times the controI v&e, does not provide adequate pmphyIaxis against thromboembolism in these patients. Moreover, there would seem to be no advantage in the use of heparin during the second haIf of the 1st trimester ta prevent fetal wastage because the incidence of spontaneous abortion is similar to that observed when the mothers are treated with eoumarin agents. Therefore, maternal risks and neonatal morbidity should be the major causes for concern in these patients. Because coumarin derivatives provide effective protect@ against thromboemboIic phenomena during pregnancy, they should be used in patients with mechanical prosthesea until the 38th week of gestation. To avoid the delivery of an anticuaguIa::d infant, it has bt :n recommended (17,3?,33) that the mother be admitted to the hospital and be given intravenous heparin, in full anticoagukutt doses, instead of the comnarin agent in the last 2 weeks of gestation. The use of heparin may be avoided hy eIective cesarean section in the 38th week (34). As noted before, b&use of the risk of perinataI in&am& hemorrhage in the fetus, emergency cesarean section is indicated if labor deveIops awhile the mother's coumarintherrylyisstinineff~.Iotbesecasesoralanticotime promptly corrected with administration of vitamin K and fresh-frozen plasma.
